Perioperative inpatient opioid consumption following autologous free-flap breast reconstruction patients: An examination of risk and patient-reported outcomes Journal Article
| Authors: | Nelson, J. A.; Polanco, T. O.; Shamsunder, M. G.; Coriddi, M.; Matros, E.; Hicks, M. E. V.; Disa, J. J.; Mehrara, B. J.; Allen, R. J. Jr; Dayan, J. H.; Afonso, A. |
| Article Title: | Perioperative inpatient opioid consumption following autologous free-flap breast reconstruction patients: An examination of risk and patient-reported outcomes |
| Abstract: | Background: The response to the unprecedented opioid crisis in the US has increased focus on multimodal pain regimens and enhanced recovery after surgery (ERAS) pathways to reduce opioid use. This study aimed to define patient and system-level factors related to perioperative consumption of opioids in autologous free-flap breast reconstruction. Methods: We conducted a retrospective study to identify patients who underwent autologous breast reconstruction between 2010 and 2016. A multivariate linear regression model was developed to assess patient and system-level factors influencing opioid consumption. Opioid consumption was then dichotomized as total postoperative opioid consumption above (high) and below (low) the 50th percentile to afford more in-depth interpretation of the regression analysis. Secondary outcome analyses examined postoperative complications and health-related quality-of-life outcomes using the BREAST-Q. Results: Overall, 601 patients were included in the analysis. Unilateral reconstruction, lower body mass index, older age, and administration of ketorolac and liposomal bupivacaine were associated with lower postoperative opioid consumption. In contrast, history of psychiatric diagnoses was associated with higher postoperative opioid consumption. There was no difference in the rates of postoperative complications when comparing the groups, although patients who had lower postoperative opioid consumption had higher BREAST-Q physical well-being scores. Conclusion: System-level components of ERAS pathways may reduce opioid use following autologous breast reconstruction, but surgical and patient factors may increase opioid requirements in certain patients. ERAS programs including liposomal bupivacaine and ketorolac should be established on a system level in conjunction with continued focus on individualized care, particularly for patients at risk for high opioid consumption. © 2021, Society of Surgical Oncology. |
| Journal Title: | Annals of Surgical Oncology |
| Volume: | 28 |
| Issue: | 12 |
| ISSN: | 1068-9265 |
| Publisher: | Springer |
| Date Published: | 2021-11-01 |
| Start Page: | 7823 |
| End Page: | 7833 |
| Language: | English |
| DOI: | 10.1245/s10434-021-10023-z |
| PROVIDER: | scopus |
| PUBMED: | 33959829 |
| PMCID: | PMC9096509 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work